The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial.
- 2022-09-26
- RCT · n = 204
- The Korean journal of internal medicine 37(6)
- Young Seok Lee
- Seong Yong Lim
- Kyung Hoon Min
- Do Jin Kim
- Kwang Ha Yoo
- Tae-Bum Kim
- Hak-Ryul Kim
- Jae Jeong Shim
- PubMed: 36153858
- DOI: 10.3904/kjim.2022.104
- High evidence
- Large Human Trial
- Clinical
At 4 days after medication, decrease of total BSS from baseline was significantly greater in the DW1601 group than in the DW16011 group (-3.51 ± 0.18 vs. -2.65 ± 0.18, p = 0.001) or P. sidoides group (-3.56 ± 0.18 vs. -2.64 ± 0.19, p < 0.001).
- Effect
- Neutral
- Effect size
- Small
- Significant
- No